FTC Challenges Amgen’s Bid to Shield Enbrel Patent Deal
WASHINGTON, D.C. — The Federal Trade Commission is urging a federal appeals court to reject Amgen Inc.’s argument that its acquisition of patent rights protecting the arthritis drug Enbrel is …
FTC Challenges Amgen’s Bid to Shield Enbrel Patent Deal Read More